Market Overview

Jazz Pharma Begins Trial of IV Administered Erwinaze

Related JAZZ
Jazz Pharma Still Loved At UBS, Firm Hikes Price Target To $210
Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic
40% Return In ~4 Months With Our IP Selected Healthcare Companies Since SA Publication (Seeking Alpha)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze^® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.

Posted-In: News FDA


Related Articles (JAZZ)

Around the Web, We're Loving...

Get Benzinga's Newsletters